Moreover, osimertinib lost its ability to decrease TRPM2 protein levels in the tested osimertinib‐resistant NSCLC cell lines as detected with Western blotting (Figure 4D) and IF (Figure S7, Supporting Information). The gene discussed is TRPM2; the disease is non-small cell lung carcinoma.